PTP4A3 and neoplasm: Compared to untreated mice, MHCC-LM3 liver tumor formation in PRL3-zumab -treated mice was visibly reduced and measurement of tumor volumes revealed a significant, 7-fold reduction in mean tumor burden between treated mice and untreated mice (Fig. 1c).